Technology & Society
Here is a Science paper by Stuart R. G. Calimport and others arguing that the WHO should comprehensively classify and stage aging, aging-related and metabolic diseases as a series of diseases and syndromes. For instance, skin aging is already classified,
“More than half of wealthy investors around the world expect to live to the age of 100, with almost two in three planning to work longer in life to afford a comfortable retirement, according to a survey on Thursday.” Read
See the documents here. Here’s what Fierce Biotech has to say: “While aspects of the framework are intended to ensure effective regenerative medicines reach patients as soon as possible, FDA commissioner Scott Gottlieb, M.D., also framed it as an attempt
Here’s a thoughtful piece by Tyler Cowan on genetic engineering. He says, “There’s a lot of innovation going on in China these days, but perhaps not all of it is good. Chinese fertility centers are going well beyond American practices,
“The White House is giving a big boost to proponents of a federal Right to Try law that they contend would give terminally ill patients easier access to medicines that haven’t won approval from the Food and Drug Administration.” From
“The legislation would give the Food and Drug Administration new powers to more rapidly approve drugs and medical devices. The measure would also include additional funding for the agency as well as more money for the National Institutes of Health.”
Another great article by the WAPO’s Ariana Eunjug Cha. Here’s a small excerpt from the piece: “As a tidal wave of new health-related gadgets, apps and tests hits the market, government agencies like the FDA, Federal Trade Commission and others
According to Nature, researchers are poised to meet with the FDA this month to discuss “medicines that delay ageing-related disease as legitimate drugs.” This makes sense, given that there are a number of scientific teams working on such compounds. Nir
From the WSJ: “A Food and Drug Administration advisory panel has recommended the first drug to help combat female sexual dysfunction. And Sprout Pharmaceuticals, which owns the pill, hopes agency approval will occur in mid-August.”
It’s rather amazing that no one has done this yet. Kudos to KQED for launching this new database. To contribute your data, click here. From the KQED blog: “It’s well known to health policy types, but less so to consumers,
From MIT Tech Review: “An infant delivered last week in California appears to be the first healthy person ever born in the U.S. with his entire genetic makeup deciphered in advance. His father, Razib Khan, is a graduate student and
I was honored to be on a panel tonight with tissue engineering pioneer Dr. Anthony Atala, Patient advocate Katie Jackson, and science artist Kelly Milukas. It was a fun panel and a great discussion about how to get more community
Here’s a well-done article by my friend Berin Szoka of the TechFreedom think tank. An excerpt: When I got tested in 2011, I was the first to ask my doctor’s office about genetic results. Exasperated with the transition to electronic
The test has been on the market since 2007, and now the FDA says something? Allowing consumers to get direct access to their own data doesn’t seem like much of a safety issue. If 23andMe’s tests are not as accurate
A similar treatment for humans has been curtailed by the FDA. If you’re a dog, this is fantastic news.
This is the latest in a series of studies to show that aging can be manipulated. If scientists were able to do for humans what these Mayo Clinic researchers did for mice, many more people would be in much better
Aaron Saenz at Singularity Hub writes a thoughtful review of 100+: What would you do with another 75 years on this Earth? Not as a pain wracked wizened elder in a nursing home, but as a vibrant super-centenarian with the
Here’s the first part of my column on the recent Congressional investigation into the genomcs industry: The genomics industry, which provides reports about disease risk, ancestry, and drug reactions based on one’s DNA, came under fire last week as a
It’s been a tough week for the personal genomics testing marketplace. First there were two long days of FDA meetings, and then today an Energy and Commerce Committee held hearings where the GAO announced the results of a “sting” operation
Was a super-interesting discussion. Recordings of the sessions are up on the web already if you missed them.